Moderna Awarded $590M to Help Accelerate Development of mRNA-Based Bird Flu Vaccine: HHS
Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, alongside other influenza vaccines, health officials announced Friday.
The U.S. Department of Health and Human Services (HHS) said in a press release that the funding will allow the pharmaceutical company to accelerate the development of an H5N1 mRNA influenza vaccine “that is well matched to strains currently circulating in cows and birds and expands the clinical data supporting the use of mRNA vaccines that may be needed if other influenza strains emerge with pandemic potential.”
Moderna said the funding will support the expansion of clinical studies “for up to five additional subtypes of pandemic influenza.”
The U.S. government previously awarded the vaccine manufacturer $176 million in July 2024 to help expedite the development of an mRNA vaccine that could be used for bird flu.
mRNA technology is the same type that was used in the development of some COVID-19 vaccines. While some vaccines use a weakened or inactive virus to stimulate an immune response, mRNA vaccines teach the body how to make proteins that can trigger an immune response and fight off an infection. (Read more from “Moderna Awarded $590M to Help Accelerate Development of mRNA-Based Bird Flu Vaccine: HHS” HERE)





